Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II neoadjuvant chemoradiation plus camrelizumab for resectable or potentially resectable locally advanced esophageal cancer
ChiCTR2100052110Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital of University of Science and Technology of China
- Start
- Oct 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab, paclitaxel and carboplatin in esophageal cancer and Esophageal Squamous Cell Carcinoma (ESCC), sponsored by The First Affiliated Hospital of University of Science and Technology of China. Primary endpoint: Pathological complete remission rate. Planned start Oct 2021; status: not yet recruiting.
02
Drugs
camrelizumabpaclitaxelcarboplatin
03
Conditions
esophageal cancerEsophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2100052110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100052110.